OS Therapies Inc’s (NYSE:OSTX) Lock-Up Period Will End on January 28th

OS Therapies’ (NYSE:OSTX) lock-up period will end on Tuesday, January 28th. OS Therapies had issued 1,600,000 shares in its initial public offering on August 1st. The total size of the offering was $6,400,000 based on an initial share price of $4.00. After the expiration of OS Therapies’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on OSTX. Maxim Group increased their price target on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, January 16th. D. Boral Capital restated a “buy” rating and set a $20.00 target price on shares of OS Therapies in a report on Wednesday, January 15th.

OS Therapies Price Performance

Shares of OS Therapies stock opened at $2.69 on Friday. OS Therapies has a 12-month low of $1.58 and a 12-month high of $7.00. The stock’s 50 day moving average is $3.37.

Insider Buying and Selling

In other news, major shareholder Shalom Auerbach sold 16,720 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total transaction of $112,692.80. Following the completion of the transaction, the insider now directly owns 2,531,211 shares in the company, valued at $17,060,362.14. The trade was a 0.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Institutional Investors Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new stake in OS Therapies Inc (NYSE:OSTX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.